Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Intuit holds investor day, reaffirms fiscal 2027 guidance
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance